Site-specific intracoronary heparin delivery in humans after balloon angioplasty: A radioisotopic assessment of regional pharmacokinetics

Circulation

Volumn 96, Issue 1, 1997, Pages 154-165

  Camenzind, Edoardo ^a,b   Bakker, Willem H ^a   Reijs, Ambroos ^a   Van Geijlswijk, Ingeborg M ^a   Boersma, Eric ^a   Kutryk, Michael J B ^a   Krenning, Eric P ^a   Roelandt, Jos R T C ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Angioplasty; Balloon; Heparin; Radioisotopes; Scintigraphy

Indexed keywords

HEPARIN;

ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; HEART SCINTISCANNING; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030762421     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.1.154     Document Type: Article

References (40)

1. Nobuyoshi M, Kimura T, Nosaka H, Mioka S, Ueno K, Yokoi H, Hamasaki N, Horiuchi H, Ohishi H. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12: 616-623.
2. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JHC, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361-371.
3. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;84:1426-1436.
4. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
5. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle cell growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
6. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;6:369-375.
7. Hermanns WRM, Rensing BJ, Strauss BH, Serruys PW. Methodological problems related to the quantitative assessment of stretch, elastic recoil and balloon-artery ratio. Cathet Cardiovasc Diagn. 1992;25:174-185.
8. Isner JM. Vascular remodeling: honey, I think I shrunk the artery. Circulation. 1994;89:2937-2941.
9. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the holy grail? (part I). Drugs. 1993;46:18-52.
10. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty: the search for the Holy Grail? (part II). Drugs. 1993;46:249-262.
11. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee K, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
12. Wolinsky H, Thung SN. Local introduction of drugs into the arterial wall: a percutaneous catheter technique. J Intervent Cardiol. 1989;2:219-228.
13. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-481.
14. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horse-radish peroxidase: a new catheter approach. Atherosclerosis. 1987; 65:215-225.
15. Fram DB, Aretz T, Azrin MA, Mitchel JF, Samady H, Gillam LD, Sahatjan R, Waters D, McKay RG. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J Am Coll Cardiol. 1994;23: 1570-1577.
16. Fernandez-Ortiz A, Meyer BJ, Mailhac A, Chesebro JH, Badimon L, Hassinger N, Owen WG, Fuster V, Badimon JJ. Intravascular local delivery: an iontophoretic approach. Circulation. 1994;89: 1518-1522.
17. Azrin MA, Mitchel JF, Fram DB, Pedersen CA, Cartun RW, Barry JJ, Bow LM, Waters DD, McKay RG. Decreased platelet deposition and smooth cell proliferation after intramural heparin delivery with hydrogel-coated balloons. Circulation. 1994;90:433-441.
18. Thomas CN, Robinson KA, Cipolla GD, Jones M, King SB III, Scott NA. In-vivo local delivery of heparin to coronary arteries with a microporous infusion catheter. J Am Coll Cardiol. 1994;23:187A. Abstract.
19. Wilensky RL, March KL, Gradus-Pizlo I, Schauwecker D, Michaels MB, Robinson J, Carlson K, Hathaway DR. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J. 1995;129:852-859.
20. Fram DB, Mitchel JF, Chow MSS, McKay RG. Pharmacokinetic modelling of intramural heparin washout following local delivery in the porcine coronary artery injury model. Circulation. 1995; 92(suppl I):I-784. Abstract.
21. Mitchel JF, Fram DB, Palme DF II, Foster R, Hirst JA, Azrin MA, Bow LM, Eldin AM, Waters DD, McKay RG. Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system: in vitro, in vivo, and clinical studies. Circulation. 1995;91: 785-793.
22. Camenzind E, Kint PP, Di Mario C, Ligthart J, van der Giessen W, Boersma E, Serruys PW. Intracoronary heparin delivery in humans: acute feasibility and long-term results. Circulation. 1995;92: 2463-2472.
23. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol E, Bulle TM, and the Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Circulation. 1990;82:1193-1202.
24. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol. 1991;68:467-471.
25. Reiber JHC, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JCH, Den Boer A, Hugenholtz PG. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantification of coronary cineangiograms. Circulation. 1985;71:280-288.
26. Haase J, Escaned J, van Swiijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, Serruys PW. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn. 1993;30:104-114.
27. Laforest MD, Colas-Linhart N, Guiraud-Vitaux F, Bok B, Bara L, Samama M, Marin J, Imbault F, Uzan A. Pharmacokinetics and biodistribution of technetium-99m labeled standard heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol. 1991;77:201-208.
28. Webster WS, Bishop SP, Geer JC. Experimental aortic intimal thickening. Am J Pathol. 1974;76:265-284.
29. Chosbanian AV, Menzoian JO, Shipman J, Heath K, Haudenschild CC. Effects of endothelial denudation and cholesterol feeding on in vivo transport of albumin, glucose, and water across rabbit carotid artery. Circ Res. 1983;53:805-814.
30. Hoover RL, Rosenberg R, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin, II: in vitro studies. Circ Res. 1980;47:578-583.
31. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res. 1980;46:625-634.
32. Mayerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic and antiplatelet drugs. In: Goodman Gilman A, Kall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. Elmsford, NY: Pergamon Press; 1990:1311-1317.
33. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980;5:204-220.
34. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982;31: 104-113.
35. Snow AD, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol. 1990;137:313-330.
36. 3H-heparin with a new site-specific drug delivery system: the D3 catheter. J Am Coll Cardiol. 1994;23:186A. Abstract.
37. Thomas CN, Robinson KA, Cipolla GD, Jones M, King SB III, Scott NA. In-vivo local delivery of heparin to coronary arteries with a microporous infusion catheter. J Am Coll Cardiol. 1994;23:187A. Abstract.
38. Fram DB, Aretz T, Azrin MA, Mitchel JF, Samady H, Gillam LD, Sahatjian R, Waters D, McKay RG. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J Am Coll Cardiol. 1994;23: 1570-1577.
39. Kulkarni PV, Parkey RW, Buja LM, Wilson JE III, Bonte FJ, Willerson JT. Technetium-labeled heparin: preliminary report of a new radiopharmaceutical with potential for imaging damaged coronary arteries and myocardium. J Nucl Med. 1978; 19:810-815.
40. Boneau B, Caranobe C, Saivin S, Dol F, Sié P. Pharmacokinetics of heparin and of dermatan sulfate: clinical implications. In: Lane DA, ed. Heparin and Related Polysaccharides. New York, NY: Plenum Press; 1992:237-247.